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Abstract Huntington’s disease (HD) is a fatal, neurode-
generative disease for which there is no known cure. Proxy
evaluation is relevant for HD as its manifestation might
limit the ability of persons to report their health-related
quality of life (HrQoL). This study explored patient–proxy
ratings of HrQoL of persons at different stages of HD, and
examined factors that may affect proxy ratings. A total of
105 patient–proxy pairs completed the Huntington’s dis-
ease health-related quality of life questionnaire (HDQoL)
and other established HrQoL measures (EQ-5D and SF-
12v2). Proxy–patient agreement was assessed in terms of
absolute level (mean ratings) and intraclass correlation.
Proxies’ ratings were at a similar level to patients’ self-
ratings on an overall Summary Score and on most of the six
Specific Scales of the HDQoL. On the Specific Hopes and
Worries Scale, proxies on average rated HrQoL as better
than patients’ self-ratings, while on both the Specific
Cognitive Scale and Specific Physical and Functional Scale
proxies tended to rate HrQoL more poorly than patients
themselves. The patient’s disease stage and mental well-
being (SF-12 Mental Component scale) were the two fac-
tors that primarily affected proxy assessment. Proxy scores
were strongly correlated with patients’ self-ratings of
HrQoL, on the Summary Scale and all Specific Scales. The
patient–proxy correlation was lower for patients at mod-
erate stages of HD compared to patients at early and
advanced stages. The proxy report version of the HDQoL is
a useful complementary tool to self-assessment, and a
promising alternative when individual patients with
advanced HD are unable to self-report.
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Proxy reports have been widely used in health services
research [1]. The subjective nature of the concept of health-
related quality of life (HrQoL) requires its assessment to be
carried out by self-report where possible. Proxy reports are
relevant when a condition could affect the ability of per-
sons to report or evaluate their subjective states [2, 3] such
as Huntington’s disease (HD). HD is an autosomal-domi-
nant progressively disabling lethal neurodegenerative dis-
order [4] characterized by a triad of movement disorder,
cognitive dysfunction and behavioural disturbances [5].
The progression of HD is viewed in five primary disease
stages [6]. At Stage 1 individuals experience slight changes
in mood and motor control and remain fully function at
home and at work. At moderate stages chorea becomes
pronounced, gait is affected and difficulties are experienced
with thinking, reasoning, speech and swallowing; individ-
uals may be able to work but at lower capacity (Stage 2) or
can no longer work and may need assistance with everyday
activities (Stage 3). In advanced stages, HD patients are no
longer able to carry out daily activities independently and
require the assistance of a carer at home (Stage 4), or need
nursing care (Stage 5). Two additional categories are Pre-
symptomatic gene positive (with critical mutation but not
yet symptomatic) and At Risk (HD family member but
genetic status not yet known). This study considers all
seven groups as persons living with HD, since the issue of
HrQoL is relevant to all.
In addition to motor impairments [7], cognitive dys-
functions [8], behavioural and psychiatric disturbances
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[9–11] and functional impairments [12], persons living
with HD may experience difficulties with insight [13] and
may display a lack of awareness [14]. For these reasons,
proxy reports in certain instances could be the only point of
reference available, as the person might be unable to report
their HrQoL or complete a questionnaire due to various
impairments caused by HD.
Studies have attempted to establish patient–proxy
agreement in evaluating HrQoL in other neurodegenerative
conditions such as Alzheimer’s disease (AD) and Parkin-
son’s disease (PD) [15–17]. Previous research with diseases
such as AD also addressed variability of patient insight
across different functional domains [18, 19] in order to better
understand barriers to self-report [20]. The purpose of the
current study was to examine patient and proxy ratings of
HrQoL of persons at different stages of HD using the Hun-
tington’s disease health-related quality of life questionnaire
(HDQoL) and to examine factors that may affect proxy
ratings. Proxies separately rated their own HrQoL using
generic instruments, to determine whether a proxy’s own
health status affects their judgement of a patient’s HrQoL.
Methods
Participants
Persons living with HD who participated in this study were
a subset of a larger validation sample for the HDQoL [21].
All were recruited through a mail-out via the Huntington’s
Disease Association (HDA) in the UK and provided their
consent prior to their inclusion in the study. From this
sample, 105 persons living with HD chose to provide proxy
data in addition to their own (At risk, n = 10; Pre-symp-
tomatic gene positive, n = 17; Stage 1, n = 9; Stage 2,
n = 8; Stage 3, n = 10; Stage 4, n = 35 and Stage 5,
n = 15). The study was approved by University of Reading
Research Ethics Committee and has been performed in
accordance with 1964 Declaration of Helsinki.
Procedure and measures
Research questionnaires were sent to persons living with
HD, referred to generically as patients although this
includes people who were not yet clinically symptomatic.
Those who volunteered to participate were invited to give
the accompanying proxy report questionnaires to someone
they felt knew them well. Patients were instructed that they
might get assistance in completing the questionnaire, from
the proxy or another helper, if they found this difficult;
however the questionnaire responses should be solely their
own. Proxies were instructed to complete the questionnaires
independently of the patient, and were asked to focus on
how they think the quality of life of the patient has been
affected, drawing upon their perceptions and thoughts as a
companion/carer. Patients and proxies were requested to
return the questionnaires using the pre-paid reply envelope
provided within a fortnight.
Patients and proxies were asked to provide demographic
details and information regarding patient’s functional
ability as an indication of disease stage. They were asked to
complete three questionnaires as follows.
1. Self- or proxy-report version, respectively, of the
HDQoL [21]. This is a disease-specific patient reported
outcome measure developed from HD patient inter-
views, where each item comprises a relevant aspect of
health-related quality of life on which HD participants
provide a self-reported response on a Likert scale. The
proxy-report version is identical to the self-reported
patient version, except that proxies are asked their own
opinion of the patient for each item. Following
exploratory factor analysis and Rasch analysis of data
from a larger sample, reported elsewhere [21], several
scales can be identified. In the present paper, we report
the Summary Scale and the six Specific Scales (i.e.
Specific Cognitive, Specific Hopes and Worries, Spe-
cific Services, Specific Physical and Functional, Spe-
cific Mood State, Specific Self and Vitality) in order
that proxy–patient agreement can be assessed both
globally and selectively. Each Specific Scale total, and
the Summary Scale, ranges from 0 (worst HrQoL) to
100 (best HrQoL).
2. Self-report version of the EQ-5D: note that proxies
were here reporting their own health status, not the
patient’s. This generic HrQoL measure comprises five
questions on mobility, self-care, pain, usual activities
and psychological status using three-point scales, and
generates a Summary Scale (1 = Best Health State)
and visual analogue scale to indicate general health
status (100 = Best Health Status) [22].
3. Self-report version of the SF-12v2: again, proxies
reported their own status. This generic measure
includes twelve items, measures eight domains of
health on five-point scales, and is used to calculate two
component scores—the Physical Component Summary
Score (PCS) and the Mental Component Summary
Score (MCS) [23]. PCS and MCS scales are trans-
formed to 0–100 scale (0 = Worst, 100 = Best).
Data analyses
All statistical tests are designated significant at p \ 0.05,
two-tailed.
Self and proxy agreement on the level of Specific and
Summary Scale scores was examined by computing mean
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scores, mean differences and their 95% confidence inter-
vals. Means were computed for the whole study sample,
and for three subgroups according to the disease stage of
persons living with HD (Early HD = At risk, Pre-symp-
tomatic gene carriers and Stage 1; Moderate HD = Stages
2 and 3; Advanced HD = Stages 4 and 5). Two-way
mixed-design analyses of variance were used to compare
the effect of the patient’s HD stage subgroup and the type
of rater (self or proxy) as independent variables on pairs of
self- and proxy-rated Specific and Summary Scale scores
(dependent variables).
Multivariate and univariate analyses of covariance were
used to examine whether proxy mean scores were
accounted for by other potential determinants in addition to
patients’ HD stage, including the proxy’s own HrQoL as
reflected in EQ-5D and SF12v2 scores, the patient’s EQ-
5D and SFv12 scores, and measures of patient–proxy
contact.
To explore agreement in terms of correlation, we
examined scatterplots of patient ratings against proxy rat-
ings. Linear regression was used to assess the relationship
between self and proxy ratings across the whole sample.
Chi-square, Fisher Exact and t tests were used to explore
associations between regression standardised residuals
(residuals above ±1.96 being defined as outliers) and other
variables such as HD stage, gender of patients or proxies.
Intraclass correlation coefficients (ICCs) with a one-way
random effects model and their respective confidence
intervals were calculated to quantify correlation between
self and proxy scores. The criteria used were the following:
ICC C 0.80 indicates excellent agreement; 0.80 [ ICC C
0.60 substantial agreement; 0.60 [ ICC C 0.40 moderate
and ICC \ 0.40 poor agreement [16, 24]. ICCs were also
calculated separately for patient HD stage subgroups and
for cases with Advanced HD who did not receive any
assistance in completing the questionnaires.
Results
Characteristics of the persons living with HD and their
proxies are summarised in Table 1. Most of the participants
with HD (87%) had confirmed positive gene status and
67% had received a clinical diagnosis. Almost all of the
proxies were spouses or partners (83%); 10% were parents;
5% were children of HD individuals and for 2% of proxies
this information was missing. Proxies spent a lot of time
per day or night caring for the person living with HD (mean
12.44 h, SD 9.59, range 0:24) and most of them (87%) had
contact on a daily basis. The average time the proxies had
known the person living with HD was 30.94 years (SD
15.49, range 1:60). One patient did not report their HD
stage, so this patient and proxy were omitted from analyses
involving HD stage, giving sample sizes of 36 for Early
HD, 18 for Moderate HD and 50 for Advanced HD. The
pair was included in whole-sample analyses (n = 105).
The self-reported EQ-5D and SF-12v2 measures show that,
as expected, patients scored worse than proxies on all
indices of HrQoL. Proxies’ physical health (SF-12v2 PCS)
was near the average of available normative data but their
mental health (MCS) fell below the population norm
[25, 26].
Figure 1 shows the patient and proxy ratings separated
by patient’s HD stage subgroup (Early, Moderate or
Advanced).
Two-way mixed-design ANOVAs, rater (self vs. prox-
y) 9 HD stage, yielded strong effects of HD stage on every
measure; Fs(2,101) ranged from 7.47 (Hopes and Worries)
to 72.8 (Physical and Functional), ps B 0.001, with HrQoL
ratings becoming progressively poorer across the three
groups. There were no significant rater 9 HD stage inter-
actions, Fs(2,101) B 2.71, suggesting that patterns of self
and proxy HrQoL scores were broadly consistent across
stages. The main effects of rater are reported in Table 2.
These were again nonsignificant on the Summary Scale and
on all Specific Scales except the Specific Hopes and
Worries Scale, where proxy ratings were significantly
better than patients’ own, and there was a trend for both the
Specific Cognitive and the Specific Physical and Func-
tional Scales’ proxy ratings to be poorer than self-ratings.
To explore what factors other than patient’s HD stage
might affect proxies’ HDQoL scores, a multivariate anal-
ysis of covariance tested the effect of HD stage along with
potential covariates on the six Specific Scales and Sum-
mary Scale. The covariates were indices obtained from
patients’ and proxies’ EQ-5D and SF-12v2 self-ratings,
plus proxy estimates of how long they had known the
patient and how much they were in contact. Over and
above the expected strong effect of HD stage, the only
variable which significantly affected proxy scores (Wilks’
lamda = 0.64, p = 0.006) was the patient’s mental state
(as measured by SF-12v2 MCS). Univariate analyses
showed that the proxy-rated scales which were affected by
patient’s MCS were Specific Hopes and Worries, Specific
Mood State, Specific Self and Vitality and the Summary
Scale—Fs(1,48) C 4.21, ps \ 0.05. All slope parameters
were positive (0.62–1.72), i.e. the proxy rating of HrQoL
improved as the patient’s MCS score improved.
The correlation between proxy and patient HDQoL
Summary score ratings is illustrated in Fig. 2 Overall there
is a strong linear relationship (b = 0.81, R2 = 0.73,
F(1,103) = 276, p \ 0.001). However outliers (where a
proxy’s score is greatly discrepant from the patient’s own)
are evident, commonly in the mid-range of HrQoL and
especially among patients with Moderate HD. There were
eight regression outliers (cases with standardised residual
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greater than ±1.96). One outlier pair (patient score of 27
and proxy score of 59) was the one whose patient did not
report their HD stage (and is therefore missing from the
plot). Among the remaining seven outlier pairs, two
patients were Early stage, four Moderate and one
Advanced. Thus, outliers were significantly more likely to
come from the Moderate HD subgroup than the other
subgroups, Fisher Exact p = 0.016. Information supplied
by the proxy implies that the patient in the eighth pair,
missing from the analysis, also probably had Moderate HD.
We explored other potential associates, including gender
of patient and proxy, nature of proxy–patient relationship,
proxy’s own HrQoL and frequency of contact. None were
significant, and there was only a trend for proxy gender,
Fisher Exact p = 0.061; seven out of eight outlier proxies
were male compared to 43 out of 97 others. This effect is
Table 1 Participant
demographics and self-reported
HrQoL scores, with mean ± SD
and range
EQ-5D EuroQol questionnaire,
SF-12v2 Short-Form Health
Questionnaire, 12-item
version 2
Persons with HD Proxies
Number of subjects 105 105
Female/male 61/44 55/50
Age 56.42 ± 12.82 (17:90) 56.55 ± 12.89 (17:90)
Full-time education (years) 13.77 ± 4.50 (4:35) 13.25 ± 4.07 (0:25)
Full or part-time employment/
retired or unemployed
20/85 49/56
EQ-5D Visual Analogue Scale (VAS) 58.38 ± 23.20 (0:100) 75.31 ± 20.31 (0:100)
EQ-5D Index Score 0.56 ± SD = 0.35 (-0.33:1) 0.78 ± 0.22 (-0.04:1)
SF-12v2 Physical Component
Score (PCS)
41.52 ± 12.78 (16.33:66.20) 50.67 ± 8.94 (30.05:64.73)
SF-12v2 Mental Component
Score (MCS)
39.95 ± 11.50 (13.89:67.34) 43.85 ± 11.25 (11.83:70.29)
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Fig. 1 Mean ratings by patients (white bars) and proxies (dark bars) ±SE, on the six Specific Scales and Summary Score of the HDQoL. Means
are shown separately for Early stage HD (n = 36), Moderate stage HD (n = 18) and Advanced stage HD patients (n = 50)
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independent from the preceding one, because Moderate
subgroup proxies were not more likely to be male than
those in other subgroups, v2 \ 1. The excess of male
proxies among outliers is not simply an extreme case of
generally poor prediction of patient HrQoL by males; after
removing all outliers, the absolute standardised residuals of
male proxies were similar to those of females (male
M = 0.68, female M = 0.65, t(95) \ 1).
Scatterplots of other subscales (not shown) show the
same pattern of lower proxy–patient agreement and more
outliers in the moderate HD group. This is confirmed by the
ICCs, see Table 3. ICC values for the whole sample
reflected excellent ([0.80) or substantial ([0.60) agreement
on all scales, as did virtually all values for the Early and
Advanced HD subgroups separately. In the Moderate HD
subgroup, agreement was moderate (\0.60) to poor (\0.40).
Agreement in the Advanced HD subgroup might have
been inflated because Advanced HD patients were more
likely than others to have reported that they received
assistance from proxies in completing the questionnaires,
(v2(2,N = 104) = 15.56, p \ 0.001). Therefore, ICCs
were recomputed for the Advanced HD subgroup after
removing the 16 cases (out of a total of 50) who received
assistance. ICCs for this subset were slightly lower than for
the whole Advanced subgroup—e.g. Summary Scale
ICC = 0.71 compared to 0.81 for the whole subgroup—but
agreement remained substantial on all scales except for
Cognitive, and Self and Vitality, where it was moderate
though still highly significant.
Discussion
Previous reports on the carers of patients with HD have
examined their reports of their own HrQoL and compared
it to that of patients [27–29]. However, the current study
using the proxy version of the HDQoL is the first in which
carers or others act as proxies, providing their own per-
ceptions of the HrQoL of persons living with HD, main-
taining a ‘proxy–proxy’ perspective [30].
Individual level correlations and group level analyses
showed that patient–proxy agreement was substantial to
excellent for the Summary Scale score of the HDQoL, and
also for most of its Specific Scales. On the Specific Hopes
and Worries Scale, proxies rated patients’ HrQoL as better
than patients’ own ratings, while on both the Specific
Cognitive Scale and Specific Physical and Functional Scale
the reverse was true. The literature shows that for chroni-
cally ill patients including those with neurological disor-
ders such as stroke [31], brain cancer [32] and Parkinson’s
disease [15, 16], patient–proxy agreement on validated
Table 2 Mean HDQoL Specific and Summary Scale scores by rater
HDQOLa Self-rated (n = 105) Proxy-rated (n = 105) ANOVA rater effectc
Mean (SD) Mean (SD) Mean diffb 95% CI F(1,101) p
Specific Scales
Cognitive 51.34 (32.24) 46.52 (33.98) 4.82 0.74 to 8.90 3.45 0.07
Hopes and Worries 50.98 (27.93) 56.89 (30.57) -5.90 -9.90 to -1.91 11.32 0.001
Services 69.71 (34.57) 72.37 (33.97) -2.65 -7.74 to 2.43 1.75 ns
Physical and Functional 62.05 (33.56) 59.97 (34.80) 2.08 -1.08 to 5.25 2.90 0.09
Mood State 58.66 (28.08) 57.42 (28.12) 1.24 -2.77 to 5.24 \1 ns
Self and Vitality 57.39 (25.78) 53.60 (26.75) 3.78 0.21 to 7.35 2.22 ns
Summary Scale 57.71 (25.03) 56.2 (26.46) 1.50 -1.21 to 4.21 \1 ns
CI confidence interval, HDQoL Huntington’s disease health-related quality of life questionnaire
a HDQOL scales are scored on a 0 (worst HrQoL) – 100 (best HrQoL) scale
b A positive mean difference indicates that self-rated scale score is higher than proxy-rated scale score
c Effect of rater (self vs. proxy) in 2-way mixed ANOVA, rater 9 HD Stage
y = 0.8073x + 12.336
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Fig. 2 Plot of patient-rated versus proxy-rated Summary Scale
scores, with regression line and 95% CIs based on all data. Symbols
represent patient’s stage of HD: bullet Early, shadowed white circle
Moderate, filled diamond Advanced
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disease-specific questionnaires are generally moderate to
high, and when discrepant, proxies often provide poorer
QoL ratings than patients [30] [33]. Our data are consistent
with the literature, but it is notable that proxies rated
patients’ Specific Hope and Worries Scale score as better
rather than worse than patients’ own ratings. This dimen-
sion may be particularly difficult for proxies to gauge as it
is perhaps even more internal than other psychosocial
dimensions, which can garner lower agreement than more
objective physical dimensions [32].
When patient–proxy agreement is examined across dis-
ease severity, the Early and Advanced subgroups showed
substantial to excellent agreement on the Summary Score as
well as for the Specific Scale scores. In both subgroups, the
highest ICC values emerged on the most ‘objective’,
observable scale—Specific Physical and Functional—as has
often been reported elsewhere [33]. Yet even the more
‘subjective’ scales such as Specific Hopes and Worries, or
Specific Mood State, yielded substantial ICCs. This may
reflect the fact that proxies were long-term companions or
close family members who typically show better agreement
than unrelated healthcare providers [17, 34]. The HDQoL
showed good patient–proxy agreement, not only with early
HD patients who could validly assess their own HrQoL, but
also with Advanced HD patients who usually have physical
or cognitive barriers to self-reporting. Good proxy–patient
agreement in the Advanced group was not merely an artefact
of proxies assisting with questionnaire completion, because
agreement remained substantial even after excluding
patients who received assistance. This is in contrast to poorer
agreement reported for more advanced stage Alzheimer’s
and Parkinson’s disease patients [15–17]. To confirm these
postal study results, further investigation where question-
naire completion is fully monitored would be useful.
For moderate Stage 2 and 3 patients, patient–proxy
agreement was moderate to poor. The QoL cancer severity
literature reports a similar pattern of results where larger
patient–proxy discrepancies were more frequent for
patients who were slightly and moderately affected [33],
rather than at extreme ends of the spectrum. This may be
due to greater scope for variability in ratings of patients and
proxies at an intermediate level of disease manifestation.
Progression of HD is suggested to be fastest, more variable
and diverse in the moderate stages, compared to early or
advanced stages of the disease [35]. Therefore, patients
with moderate HD might be the most heterogeneous group
and most changeable over time, making it hard for proxies
to form stable judgements. Furthermore, the moderate
stages may be particularly complex for patients, who are
beginning to experience a physical and psychological
decline which both they and their family have long drea-
ded. They may be anxious about other people’s attitudes, or
wrongly believe that transient difficulties are signs of HD,
as we have previously found [36]. Some proxies may find it
hard to communicate with patients and understand their
subtle and fluctuating symptoms at this stage, and our
analysis hints that this may be particularly true of male
proxies. By comparison, advanced-stage patients’ state and
relations with carers are more stable, perhaps making it
easier for proxies to evaluate HrQoL. It is also worth noting
that the ‘proxy–proxy’ perspective adopted here—where
proxies were encouraged to use their own viewpoint, rather
than explicitly trying to ‘simulate’ the patient’s feelings—
can lead to genuine differences between proxy and patient
views of HrQoL [30].
We examined factors that might influence proxies’
tendency to over- or under-rate HrQoL. Previous studies
have suggested that proxies’ level of burden, psychosocial
stress and amount of time they spend with patients could
moderate their assessment [1, 37–39]. In the present case,
neither proxies’ own physical or psychosocial HrQoL (as
putative measures of carer burden), nor their degree of
Table 3 Intraclass correlation coefficients between self and proxy scores for the HDQoL Specific and Summary Scales: whole sample and HD
stage subgroups
HDQoL Whole sample (n = 105) Early HD (n = 36) Moderate HD (n = 18) Advanced HD (n = 50)
ICC (95% CI) ICC (95% CI) ICC (95% CI) ICC (95% CI)
Specific Scales
Cognitive 0.79 (0.71–0.85) 0.78 (0.61–0.88) -0.03 (-0.47 to 0.42) 0.61 (0.40–0.76)
Hopes and Worries 0.74 (0.63–0.81) 0.83 (0.69–0.91) 0.49 (0.05 to 0.77) 0.77 (0.63–0.86)
Services 0.71 (0.60–0.79) 0.76 (0.58–0.87) 0.48 (0.04 to 0.76) 0.74 (0.59–0.85)
Physical and Functional 0.88 (0.84–0.92) 0.87 (0.77–0.93) 0.24 (-0.23 to 0.63) 0.81 (0.69–0.89)
Mood State 0.73 (0.63–0.81) 0.56 (0.29–0.75) 0.46 (0.02 to 0.76) 0.76 (0.61–0.85)
Self and Vitality 0.75 (0.65–0.82) 0.63 (0.39–0.79) 0.65 (-0.28 to 0.85) 0.59 (0.37–0.74)
Summary Scale 0.85 (0.79–0.90) 0.81 (0.65–0.90) 0.37 (-0.09 to 0.70) 0.81 (0.69–0.89)
HD Huntington’s disease, ICC intraclass correlation coefficient, CI confidence interval, HDQoL Huntington’s disease health-related quality of
life questionnaire
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contact with the patient, influenced the level of proxy rat-
ings. However, the patient’s own psychological state
(SF-12v2 Mental Component score) influenced proxy
scores on the more ‘subjective’ Specific Scales of the
HDQoL—Specific Hopes and Worries, Specific Mood
State, Specific Self and Vitality—even after the patient’s
disease stage was taken into account. Therefore, proxies’
ratings of psychosocial aspects of HrQoL were sensitive to
patients’ psychological state, as well as symptom severity.
In summary, this cross-sectional study addressed
parameters of patient–proxy agreement on HrQoL for the
first time in HD, by comparing proxy assessment with
patient self-report, using the disease-specific HDQoL.
There was substantial agreement for the Summary Scale
and also the Specific Scales and this suggests that the
HDQoL proxy version yields generally similar scores to
patients’ own, particularly on physical and functional
aspects but also on more ‘subjective’ scales. On the Specific
Hopes and Worries Scale, proxies on average rated HrQoL
as better than patients’ self-ratings, while on both the Spe-
cific Cognitive and Specific Physical and Functional Scales
proxies tended to rate HrQoL more poorly than patients
themselves. As more modest patient–proxy agreement was
found for moderate-stage patients, proxy report should not
be used as a substitute for patient-reported rating for these
patients. As there was good patient–proxy agreement for
advanced-stage patients, proxy evaluation using this ques-
tionnaire could be a particularly useful complementary tool
to self-report in advanced HD.
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